FDA Accepts Review of Supplemental Biologics License Application for First-Line Cemiplimab/Chemo in Advanced NSCLC

Article

The supplemental biologics license application for cemiplimab plus chemotherapy for patients with advanced non–small cell lung cancer was based on findings from the phase 3 EMPOWER-Lung 3 study and was accepted for review by the FDA.

A supplemental biologics license application for first-line PD-1 inhibitor cemiplimab-rwlc (Libtayo) plus chemotherapy for patients with advanced non–small cell lung cancer (NSCLC) was accepted for review by the FDA, according to a press release from developer Regeneron Pharmaceuticals.1

The application was supported by findings from the phase 3 EMPOWER-Lung 3 trial (NCT03409614), the results of which were presented at the 2021 European Society for Medical Oncology Congress.2 Investigators reported that patients treated with the cemiplimab/chemotherapy combination achieved a 12-month overall survival (OS) rate of 65.7% (95% CI, 59.9%-70.9%) compared with 56.1% (95% CI, 47.5%-63.8%) for those treated with placebo and chemotherapy. Moreover, after a median follow-up duration of 16.4 months, patients in the investigational arm had a median OS of 21.9 months (95% CI, 15.5–not evaluable [NE]) compared with 13.0 months (95% CI, 11.9-16.1) in the control arm.

The FDA has a target action date of September 19, 2022.

Those in the experimental arm were treated with 350 mg of cemiplimab ever 3 weeks plus investigator's choice of platinum doublet chemotherapy every 3 weeks for 4 cycles. In the placebo arm, patients received the same chemotherapy backbone plus placebo. A total of 466 patients with treatment-naive advanced stage IIIb/c NSCLC with non-squamous and squamous histology were enrolled on the study.

Additional findings from the study indicated that patients in the cemiplimab arm had a 12-month progression-free survival (PFS) rate of 38.1% (95% CI, 32.4%-43.8%) compared with 16.4% (95% CI, 10.5%-23.4%) with chemotherapy. After a median follow-up duration of 16.4 months, the median PFS was 8.2 months (95% CI, 6.4-9.3) and 5.0 months (95% CI, 4.3-6.2) in the experimental and control arms, respectively.

Investigators observed an overall response rate of 43.3% (95% CI, 37.7%-49.0%) and 22.7% (95% CI, 16.4%-30.2%) in the cemiplimab and chemotherapy arms, respectively (OR, 2.68; 95% CI, 1.72-4.19; P <.0001). Patients in both arms had a median duration of response of 15.6 months (12.4-NE) and 7.3 months (95% CI, 4.3-12.6), respectively.

In terms of safety, 3% of patients discontinued treatment due to any grade adverse effects (AEs) and 4% due to grade 3 to 5 AEs in the cemiplimab arm vs 3% and 3%, respectively, in the placebo arm. Moreover, 3% and 2% of patients in the cemiplimab arm discontinued treatment due to any grade and grade 3 to 5 treatment-related AEs compared with 1 patient each in the placebo arm, respectively.

The most common any grade treatment-emergent AEs (TEAEs) in the cemiplimab arm were anemia (44%), decreased appetite (17%), and fatigue (12%), and grade 3 to 5 TEAEs included anemia (10%), neutropenia (6%), and thrombocytopenia (3%). In the placebo arm, the most common any grade TEAEs were alopecia (43%), anemia (40%), and nausea (16%), with grade 3 to 5 TEAEs including anemia (7%) and neutropenia (6%).

References

  1. FDA accepts for review LIBTAYO® (cemiplimab-rwlc) in combination with chemotherapy for first-line treatment of advanced NSCLC. News release. Regeneron Pharmaceuticals. January 19, 2022. Accessed January 19, 2022. https://bit.ly/3GMkjKo
  2. Gogishvili M, Melkadze T, Makharadze T, et al. EMPOWER-Lung 3: cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:10.1016/annonc/annonc741
Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Patrick Forde, MBBCh, with the Oncology Brothers presenting slides
Patrick Forde, MBBCh, with the Oncology Brothers presenting slides